New Indian price policy will cut pharma revenues by 17%
This article was originally published in Scrip
India's new national pharmaceutical pricing policy, that marks a shift to a market-based approach to rein in prices from the over three decade old cost-based one, will close to double the span of control, shave prices of essential drugs and slice industry's revenues by an estimated 17%.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.